Pharmakotherapie - Physostigmin post OP

Zusammenfassung

Physostigmin, ein reversibler Acteylcholinesterasehemmer, ist Mittel der Wahl in der Therapie postoperativer Vigilanzstörungen. Sie entstehen durch Blockade zentral cholinerger Neurone und/oder Acetylcholinmangel und werden unter dem Begriff Zentral-Anticholinerges Syndrom zusammengefasst. Physostigmin findet seinen Einsatz ebenfalls in der Therapie des postoperativen shiverings, bei Intoxikationen, in der antideliranten Therapie und in der Schmerztherapie.

Abstract

The central anticholinergic syndrome should be considered in patients with altered mental status following anaesthesia. Physostigmine, a reversible acetylcholinesterase inhibitor, is a first-line medicament for the therapy of the central anticholinergic syndrome. Physostigmine crosses the blood-brain barrier and elevates acetylcholine levels in the brain. For prevention of postanaesthetic shivering, for treatment of intoxications and postoperative pain, and for patients suspected of having antimuscarinic delirium physostigmin is also indicated.

Schlüsselwörter:

Pharmakotherapie - Anästhesie - Acetylcholin - Physostigmin - ZAS

Key words:

Phamacotherapy - Physostigmine -Anticholinergic syndrome

Literatur

• 1 Anticholium® ,Gebrauchsinformation. Dr. Franz Köhler Chemie GmbH
• 2 Longo VG. Behavioral and electroencephalographic effects of atropine and related compounds.  Pharmacol Rev. 1966;  18 965-996
• 3 Link J, Papadopoulos G, Dopjans D, Guggenmoos-Holzmann I, Eyrich K. Distinct central anticholinergic syndrome following general anesthesia.  Eur J Anaesthesiol. 1997;  14 15-23
• 4 Rupreth J, Dworacek B. The central anticholinergic syndrome in the postoperative period.  In: Nunn JF, Utting JE, Brown BR eds. General Anaesthesia 5th Edn.  London: Butterworth. 1989;  1141-1148
• 5 Rupreth J, Dworacek B. Central anticholinergic syndrome during postoperative period.  Ann Fr Anesth Reanim. 1990;  9 295-304
• 6 Senne I, Zourelidis C, Irnich D, Kurz M, Hummel T, Zwissler B. Rezidivierende Bewusstlosigkeit und Atemstillstand nach Allgemeinanästhesie.  Anaesthesist. 2003;  52 608-611
• 7 Hall RCW, Fox J, Stickney SK. Anticholinergic delirium: etiology, presentation, diagnosis and management.  J Psychoactive Drugs. 1978;  10 237-241
• 8 Brown DV, Heller F, Barkin R. Anticholinergic syndrome after anesthesia: a case report and review.  AM J Ther. 2004;  11 144-153
• 9 Ries NL, Dart RC. New Developments in Antidotes.  Med Clin N Am. 2005;  89 1379-1397
• 10 Horn EP, Standl T, Sessler DI, Knobelsdorff G von, Buchs C, Schulte J am Esch. Physostigmin e prevents postanaesthetic shivering as does meperidine or clonidine.  Anesthesiology. 1998;  88 108-113
• 11 Röhm KD, Riechmann J, Boldt J, Schuler S, Suttner SW, Piper SN. Physostigmin e for the prevention of postanaesthetic shivering following general anaesthesia- a placebo-controlled comparison with nefopam.  Anaesthesia. 2005;  60 433-438
• 12 Beilin B, Bessler H, Papismedov L, Weinstock M, Shavit Y. Continuous Physostigmin e combined with morphine-based-patient-controlled analgesia in the postoperative period.  Acta Anaesthesiol. Scand. 2005;  49 78-84
• 13 Schneir AB, Offerman SR, Ly BT, Davis JM, Baldwin RT, Williams SR, Clark RF. Complications of diagnostic Physostigmin e administration to emergency department patients.  Annals of Emergency Medicine. 2003;  42 14-19